Sylvie P. Froidevaux

Allschwil, BL, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.

The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.

Journal: The Journal of pharmacology and experimental therapeutics

Published: June 15, 2024

Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity.

Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity.

Journal: Journal of medicinal chemistry

Published: March 14, 2024

Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold.

Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold.

Journal: Journal of medicinal chemistry

Published: February 13, 2024

Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases.

Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases.

Journal: Journal of medicinal chemistry

Published: February 13, 2024

Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.

Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.

Journal: Journal of medicinal chemistry

Published: March 08, 2023

Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.

Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.

Journal: Journal of medicinal chemistry

Published: August 15, 2022

Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases.

Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases.

Journal: Journal of medicinal chemistry

Published: August 10, 2022

Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren's syndrome.

Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren's syndrome.

Journal: Arthritis research & therapy

Published: March 03, 2021

Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus.

Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus.

Journal: RMD open

Published: April 06, 2020

Evaluating survey methods for bat roost detection in ecological impact assessment.

Evaluating survey methods for bat roost detection in ecological impact assessment.

Journal: Animal conservation

Published: October 15, 2019

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Journal: Pharmacology research & perspectives

Published: August 30, 2017

A chromosomal region on ECA13 is associated with maxillary prognathism in horses.

A chromosomal region on ECA13 is associated with maxillary prognathism in horses.

Journal: PloS one

Published: August 22, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026